

Efficacy of Sorafenib in Patients with Hepatocellular Carcinoma Refractory to Transarterial Chemoembolization

Tadaaki Arizumi, Tomohiro Minami, Masashi Kono, Hirokazu Chishina, Masahiro Takita, Satoru Hagiwara, Yasunori Minami, Toshiharu Sakurai, Kazuomi Ueshima, Naoshi Nishida and Masatoshi Kudo*

Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Japan

*Corresponding author: Masatoshi Kudo, Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, 377-2 Ohno-Higashi, Osaka-Sayama 589-8511, Japan



ARTICLE INFO

Received:  February 09, 2019

Published:  February 19, 2019

Citation: Tadaaki A, Tomohiro M, Masashi K, Hirokazu C, Masahiro T, Satoru H, Yasunori M, Toshiharu S, Kazuomi U, Naoshi N, Masatoshi K. Efficacy of Sorafenib in Patients with Hepatocellular Carcinoma Refractory to Transarterial Chemoembolization. Biomed J Sci & Tech Res 14(5)-2019. BJSTR. MS.ID.002610.

Keywords: Hepatocellular carcinoma; Intermediate stage; Sorafenib; TACE refractoriness

ABSTRACT

Background: Transcatheter arterial chemoembolization (TACE) refractoriness is an indication for sorafenib treatment in patients with intermediate-stage hepatocellular carcinoma (HCC). This study aims at evaluating the efficacy of conversion of treatment to sorafenib on overall survival (OS) among trans arterial chemoembolization (TACE)-refractory HCC patients.

Methods: This retrospective cohort study included 497 patients with HCC treated with TACE between January 2008 and December 2013 at the Kindai University Hospital. Among those patients, 56 were considered refractory to TACE. These TACE-refractory patients were grouped into two cohorts:

- a) patients who switched treatment from TACE to sorafenib (sorafenib group) and
- b) those who continued TACE (TACE group). We evaluated the OS of patients from the initial TACE.

Results: Thirty-two patients were classified into the sorafenib group, while 24 patients were in the TACE group. The median OS from the initial TACE was 4.29 years in the sorafenib group and 2.14 years in the TACE group ($p < 0.0010$).

Conclusion: Conversion of treatment to sorafenib might improve the OS in TACE-refractory patients with intermediate-stage HCC. Hence, conversion of treatment should be considered for HCC patients refractory to TACE.

Introduction

Hepatocellular carcinoma (HCC) is the third most common cause of cancer-related death worldwide, with an escalating global incidence and mortality [1]. In Japan, nationwide follow-up surveys by the Liver Cancer Study Group of Japan revealed that the total number of deaths from liver cancer increased steadily in 1975 but have been declining since its peak in 2004. The establishment of a nationwide HCC surveillance program in Japan has contributed to the improvement of overall survival (OS). Transcatheter arterial chemoembolization (TACE) is indicated as the first-line treatment for patients with intermediate-stage HCC [2]. On the contrary,

sorafenib, which demonstrated survival benefit in the SHARP trial/Asia-Pacific trial, is applied for cases with advanced stage of HCC [3-6]. For example, sorafenib is indicated for cases with extrahepatic metastasis and vascular invasion. However, HCC patient's refractory to TACE should also be treated with sorafenib before the progression to advanced stage because continuous TACE may lead to deterioration of liver function. From this point of view, the timing of switching treatment from TACE to sorafenib is critical for the management of HCC [7]. This study aimed to address this important issue and compare OS from the initial TACE between

patients who continued TACE and those switched to sorafenib after refractoriness to TACE was observed.

Materials and Methods

Patients

The derivation dataset included 497 patients who underwent TACE for HCC at Kindai University between 2008 and 2013. All patients satisfied the diagnostic criteria for HCC proposed by the Japan Society of Hepatology (JSH) [8]. The diagnosis of HCC was made based on histology or radiologic findings using contrast-enhanced computed tomography (CE-CT) and/or dynamic magnetic resonance imaging (MRI). The selection of treatment was based on discussions involving multidisciplinary teams at our institution. Among these patients, intermediate-stage HCC patients who underwent multiple TACE sessions were retrospectively identified from medical records. Patients deemed refractory to TACE were further identified among the patients treated with repeated TACE. Then, these TACE-refractory patients were subdivided into two cohorts:

- patients who switched from TACE to sorafenib (sorafenib group) or
- patients continued TACE despite the suspicion of being refractory to TACE (TACE group).

The inclusion criteria were as follows:

- patients with HCC diagnosed based on histological examination or typical radiological findings (early enhancement followed by late wash-out on CE-CT or dynamic MRI) and HCC refractory to radiofrequency ablation and surgical resection based on the indications for TACE,
- Barcelona Clinic Liver Cancer (BCLC) stage B (intermediate stage),
- performance status of 0 or 1, and
- Child-Pugh class A or B liver function.

The exclusion criteria were

- concomitant antineoplastic treatment,
- BCLC stage C (advanced stage), and

- history of hepatic arterial infusion chemotherapy/systemic therapy after being refractory to TACE.

Clinicopathological variables including demographics, alpha-fetoprotein (AFP), Child-Pugh class, and BCLC prognostic scores were collected at the time of referral to our unit, prior to treatment.

Definition of TACE Refractoriness

CE-CT is performed within 3 months of the TACE procedure to evaluate the radiological response of the tumor. Follow-up CT or MRI is performed every 3–4 months. In addition, AFP levels are evaluated every 2–3 months. The definition of TACE refractoriness is based on the JSH Consensus Guidelines [9]. The radiological response to TACE was evaluated on initial CT/MRI within 3 months after the latest TACE. The response of serum tumor marker levels was also evaluated after 2 months of the latest TACE. The increase in serum AFP level at >20% from baseline, within 2 months after the latest TACE, was considered continuous elevation of AFP level. For the assessment of response based on the AFP level, only patients with baseline AFP of >20 ng/ml were included.

Statistical Analysis

Survival curves were estimated using the Kaplan-Meier method with the primary endpoint of death for OS analysis from initial TACE. Patients who did not meet the endpoint were censored at the time of the last visit. Comparison of survival periods among the groups was estimated using the log-rank test. A P value of <0.05 was considered statistically significant. All analyses were performed using SAS statistical software version 8.2 (SAS Institute, Cary, NC, USA).

Results

Patient Characteristics

Among 497 patients who received TACE, 56 patients were considered refractory to TACE. The baseline characteristics of patients are summarized in Table 1. Forty patients (71.4%) were positive for anti-hepatitis C virus antibody (HCV Ab), four patients (7.1%) were positive for hepatitis B virus (HBV) surface antigen (HBs-Ag), and 12 patients (21.4%) were negative for both HCV Ab and HBs-Ag. All patients were asymptomatic with a performance status of 0. Forty-eight patients (85.7%) were classified as Child-Pugh class A.

Table 1: Baseline patient and disease characteristics.

	Number of cases n=56	(%)
Age		
Median (25–75%)*	72.5 (67.5–77)*	
Gender		
Male	38	(67.9)
Female	18	(32.1)
ECOG PS		
0	56	(100)
1	0	(0)

Child-Pugh class		
A	48	(85.7)
B	8	(14.3)
Virus status†		
HBV	4	(7.1)
HCV	40	(71.4)
Virus negative	12	(21.4)
Previous therapy ‡		
Surgical resection	14	(25)
Radiofrequency ablation	32	(57.1)
Cytotoxic chemotherapy	7	(12.5)
Alpha-fetoprotein -median (25-75%)* ng/ml	33 (10-162.75)*	

ECOG, Eastern Cooperative Oncology Group; HBV, hepatitis B virus; HCV, hepatitis C virus; PS, performance status

*Dispersion variables are shown as median values (25-75%)

†Cases positive for hepatitis B virus surface antigen were regarded as cases of HBV-related HCC and cases positive for hepatitis C antibody were regarded as cases of HCV-related HCC

‡Patients may have received more than one type of therapy.

Treatment After TACE Refractoriness

Of the patients deemed refractory to TACE, 32 patients were classified in the sorafenib group and 24 patients in the TACE group. Of the 56 patients (32 in the sorafenib group and 24 in the TACE group), 38 died during the study period (19 in the sorafenib group and 19 in the TACE group), 8 survived (5 in the sorafenib group and 3 in the TACE group), and 10 were lost to follow-up (8 in the

sorafenib group and 2 in the TACE group). The median OS from the initial TACE of the entire cohort was 3.0 years (95% confidence interval (CI) 2.30–3.61 years). The median OS from the initial TACE was 2.14 years (95 % CI 1.51–2.83 years) and 4.29 years (95 % CI 3.15–5.74 years) for the patients in the TACE and sorafenib groups, respectively. Pairwise comparisons verified a significantly longer OS for patients in the sorafenib group than those in the TACE group ($P < 0.001$, log-rank test) (Figure 1).




Figure 1: Comparison of overall survival between transcatheter arterial chemoembolization and sorafenib in patients who were refractory to TACE. Kaplan-Meier curves of the overall survival of 56 patients who underwent treatment with continuous TACE or conversion to sorafenib after being considered refractory to TACE. The median overall survival of the patients in the TACE and sorafenib groups was 2.14 and 4.29 years, respectively, after being thought refractory to TACE ($P < 0.001$ by log-rank test).

Discussion

Ogasawara et al. compared the efficacy of sorafenib treatment and continuation of TACE in HCC patients after being refractory to TACE and reported that OS and time to disease progression were longer in patients who switched from TACE to sorafenib than in those who received continuous TACE [10]. Our study also confirmed that after refractoriness to TACE was observed, OS could be improved by switching to sorafenib among the patients with intermediate-stage HCC and TACE refractoriness. This study demonstrated that OS from the initial TACE was longer in the sorafenib group than that in the TACE group among TACE-refractory HCC patients. Although TACE is effective in cases with multiple nodules, repeated TACE could result in the obstruction of tumor vessels [11]. In addition, tumor progression may lead to incomplete embolization because of the invasive tumor characteristics without fibrous capsule. Because the antitumor effect of TACE should be counterbalanced by the deterioration of liver function, which is one of the adverse events of TACE, continuation of TACE in refractory cases should be avoided. Conversely, recent progress in HCC treatment, including molecular targeted agents, allows us to select various treatments: the degree of liver function has generally been considered in the selection of treatment in HCC cases [12-16]. Furthermore, in addition to the conventional HCC treatments, several clinical trials are being conducted such as on immune checkpoint inhibitor for HCC; it is quite possible that TACE would be replaced by systemic therapy in considerable number of HCC cases with intermediate stage [17-19]. Although TACE is indicated for patients with intermediate-stage HCC under the current algorithm, tyrosine kinase inhibitors, such as sorafenib or lenvatinib, is selected in many cases that demonstrate refractoriness to TACE.

Conclusion

In conclusion, it is likely that switching to sorafenib improves OS from initial TACE in TACE-refractory patients with intermediate-stage HCC; chemoembolization should not be repeated if tumors are uncontrolled by previous TACE. To improve the survival of HCC patients, it is important to switch treatment from TACE to systemic therapy, such as sorafenib, in cases that demonstrate refractoriness to TACE even if HCC is still in the intermediate stage.

Disclosure Statement

Kudo M: Honoraria from Bayer, Eisai, MSD, Ajinomoto. Consulting or advisory role for Kowa, MSD, BMS, Bayer, Chugai, Taiho. Research funding from Chugai, Otsuka, Takeda, Taiho, Sumitomo Dainippon, Daiichi Sankyo, MSD, Eisai, Bayer, Abbvie.

References

1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, et al. (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. *Int J Cancer* 136: E359-386.
2. Bruix J, Reig M, Sherman M (2016) Evidence-Based Diagnosis, Staging, and Treatment of Patients with Hepatocellular Carcinoma. *Gastroenterology* 150: 835-853.
3. Cucchetti A, Piscaglia F, Pinna AD, Djulbegovic B, Mazzotti F, et al. (2017) Efficacy and Safety of Systemic Therapies for Advanced Hepatocellular Carcinoma: A Network Meta-Analysis of Phase III Trials. *Liver Cancer* 6: 337-348.
4. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, et al. (2008) Sorafenib in advanced hepatocellular carcinoma. *N Engl J Med* 359: 378-390.
5. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, et al. (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. *Lancet Oncol* 10: 25-34.
6. Moriguchi M, Aramaki T, Nishiofuku H, Sato R, Asakura K, et al. (2017) Sorafenib versus Hepatic Arterial Infusion Chemotherapy as Initial Treatment for Hepatocellular Carcinoma with Advanced Portal Vein Tumor Thrombosis. *Liver Cancer* 6: 275-286.
7. Piscaglia F, Ogasawara S (2018) Patient Selection for Transarterial Chemoembolization in Hepatocellular Carcinoma: Importance of Benefit/Risk Assessment. *Liver Cancer* 7: 104-119.
8. Kudo M, Izumi N, Kokudo N, Matsui O, Sakamoto M, et al. (2011) Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. *Dig Dis* 29: 339-364.
9. Kudo M, Matsui O, Izumi N, Kadoya M, Okusaka T, et al. (2014) Transarterial Chemoembolization Failure/Refractoriness: JSH-LCSGJ Criteria 2014 Update. *Oncology* 87 Suppl 1: 22-31.
10. Ogasawara S, Chiba T, Ooka Y, Kanogawa N, Motoyama T, et al. (2014) Efficacy of Sorafenib in Intermediate-Stage Hepatocellular Carcinoma Patients Refractory to Transarterial Chemoembolization. *Oncology* 87: 330-341.
11. Arizumi T, Ueshima K, Chishina H, Kono M, Takita M, et al. (2014) Validation of the criteria of transcatheter arterial chemoembolization failure or refractoriness in patients with advanced hepatocellular carcinoma proposed by the LCSGJ. *Oncology* 87 Suppl 1: 32-36.
12. Kudo M (2018) Lenvatinib May Drastically Change the Treatment Landscape of Hepatocellular Carcinoma. *Liver Cancer* 7: 1-19.
13. Kudo M, Finn RS, Qin S, Han KH, Ikeda K, et al. (2018) Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. *Lancet* 391: 1163-1173.
14. Kudo M (2017) Systemic Therapy for Hepatocellular Carcinoma: 2017 Update. *Oncology* 93 Suppl 1: 135-146.
15. Bruix J, Qin S, Merle P, Granito A, Huang YH, et al. (2017) Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet* 389: 56-66.
16. Kudo M, Ueshima K, Yokosuka O, Ogasawara S, Obi S, et al. (2018) Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial. *Lancet Gastroenterol Hepatol* 3: 424-432.
17. Kudo M (2017) Immuno-Oncology in Hepatocellular Carcinoma: 2017 Update. *Oncology* 93 Suppl 1: 147-159.
18. Nishida N, Kudo M (2018) Immune checkpoint blockade for the treatment of human hepatocellular carcinoma. *Hepatol Res* 48(8): 622-634.
19. El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, et al. (2017) Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. *Lancet* 389: 2492-2502.

ISSN: 2574-1241

DOI: 10.26717.BJSTR.2019.14.002610

Masatoshi Kudo. Biomed J Sci & Tech Res



This work is licensed under Creative Commons Attribution 4.0 License

Submission Link: <https://biomedres.us/submit-manuscript.php>



Assets of Publishing with us

- Global archiving of articles
- Immediate, unrestricted online access
- Rigorous Peer Review Process
- Authors Retain Copyrights
- Unique DOI for all articles

<https://biomedres.us/>